NUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nu Skin Enterprises Inc (NUS) is not a strong buy at the moment for a beginner investor with a long-term focus. The company's recent financial performance shows significant declines in revenue, net income, and EPS, while the technical indicators and trading trends do not suggest a strong upward momentum. Additionally, the options data indicates a bearish sentiment with a higher put-call volume ratio. Given the lack of positive catalysts and no strong proprietary trading signals, it is advisable to hold off on investing in this stock for now.
The MACD is positive and expanding, which is a mildly bullish signal. However, the RSI is neutral at 46.017, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 7.213, with resistance at 7.389 and support at 7.037. Overall, the technical indicators do not suggest a strong buy signal.
The appointment of Chelsea Lantz as interim CFO and the company's commitment to succession planning could provide stability and support future growth. Additionally, the gross margin increased by 12.91% YoY, showing some operational efficiency.
Significant declines in revenue (-16.89% YoY), net income (-140.14% YoY), and EPS (-139.73% YoY) in the latest quarter indicate poor financial performance. The stock price fell after the CFO announcement, reflecting market concerns. Options data shows bearish sentiment with a higher put-call volume ratio.
In Q4 2025, revenue dropped to $370.32 million (-16.89% YoY), net income fell to $14.49 million (-140.14% YoY), and EPS declined to $0.29 (-139.73% YoY). However, gross margin improved to 70.74% (+12.91% YoY). Overall, the financial performance is weak, with significant declines in key metrics.
No recent analyst rating or price target changes are available for NUS.
